Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vera TherapeuticsVERA +9.48%34 Debt-to-Equity is 0.19 as of Jun. 2026, which is 19% above its 10-year median of 0.16. GuruFocus rates VERA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 970 Biotechnology companies, Vera Therapeutics ranks worse than 53.3% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vera Therapeutics's Debt-to-Equity or its related term are showing as below:
VERA'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.16 Max: 0.53
Current: 0.19
During the past 7 years, the highest Debt-to-Equity Ratio of Vera Therapeutics was 0.53. The lowest was 0.00. And the median was 0.16.
VERA's Debt-to-Equity is ranked worse than 53.3% of 970
companies
in the Biotechnology industry
Industry Median: 0.15
vs VERA: 0.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vera Therapeutics Debt-to-Equity Related Terms
Vera Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vera Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VERA vs TARS, IMNM, BEAM: Debt-to-Equity Comparison
For the Biotechnology subindustry, Vera Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vera Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vera Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vera Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vera Therapeutics (VERA) has a Debt-to-Equity of 0.19 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vera Therapeutics and its competitors. This is 19% above median its historical median of 0.16. According to the industry distribution chart, Vera Therapeutics ranks #517 out of 970 companies in the Biotechnology industry, placing it in the top 53.3%.
Is Vera Therapeutics' Debt-to-Equity too high?
Vera Therapeutics' current Debt-to-Equity of 0.19 is 19% above median its 10-year median of 0.16. The Biotechnology industry median Debt-to-Equity is 0.15. Vera Therapeutics' value of 0.19 is 26.7% above this industry median. Based on the distribution chart, Vera Therapeutics ranks #517 out of 970 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vera Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Vera Therapeutics' Debt-to-Equity compare to TARS and IMNM?
According to the Biotechnology industry distribution chart, Vera Therapeutics ranks #517 out of 970 companies for Debt-to-Equity. This places Vera Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Vera Therapeutics' value of 0.19 is 26.7% above this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 0.15, Vera Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vera Therapeutics's current Debt-to-Equity of 0.19 is 26.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vera Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vera Therapeutics's current Debt-to-Equity is 0.19, which is 19% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vera Therapeutics stock overvalued right now?
Vera Therapeutics (VERA) has a current Debt-to-Equity of 0.19. The current Debt-to-Equity is 0.19, which is 19% above median its 10-year median of 0.16 and 26.7% above the Biotechnology industry median of 0.15. Vera Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vera Therapeutics (VERA), the current Debt-to-Equity is 0.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
34GF Score
Get the complete analysis for VERA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VERA has been successfully added to your 
